The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
REGULATORY
Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
The pharmaceutical industry strongly opposes a simple expansion of the current rule to deduct the price maintenance premium (PMP) from PMP-granted comparator drugs in the pricing of new medicines deemed PMP-ineligible, but might accept such deduction if no PMP-eligible indications…
To read the full story
Related Article
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
REGULATORY
- Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
April 21, 2021
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
April 20, 2021
- Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
April 20, 2021
- Japan to Secure Enough Vaccines for All People by September: Suga
April 20, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…